ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Engineering Microbial Particles for Next-Generation Biomedical Platforms.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In vivo CAR-M therapy: advancing precision delivery and programmable immune remodeling.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Microbe-derived particles (MDPs), which include extracellular vesicles, outer membrane vesicles, inclusion bodies, polysaccharide particles, and virus-like particles, represent a rapidly expanding category of bioinspired nanomaterials. With their natural origin, intrinsic biocompatibility, and highly programmable functionality, MDPs serve as a versatile bridge between living microbial systems and engineered nanomaterials. This review systematically outlines the diverse classes, biosynthetic pathways, physicochemical properties, and biomedical applications of MDPs. We summarize recent progress in their use for drug delivery, vaccine design, immune modulation, and diagnostic imaging, emphasizing how bioengineering approaches enable precise control over their composition and targeting capabilities. Additionally, we examine advancing methodologies for scalable manufacturing and accurate characterization-such as omics-based profiling and advanced imaging techniques. Finally, we discuss current challenges and future prospects for integrating synthetic biology with materials science to develop next-generation intelligent biological platforms based on MDPs. This comprehensive overview aims to foster the rational design and translational deployment of MDP-based systems across biomedical, biotechnological, and materials science fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.